UNAUDITED PRO FORMA CONDENSED COMBINED FINANICAL STATEMENTSSolta Medical Inc • January 11th, 2012 • Electromedical & electrotherapeutic apparatus
On September 12, 2011, Solta Medical, Inc. (“Solta or the Company”) entered into a stock purchase agreement (“Purchase Agreement”) with Medicis Pharmaceutical Corporation (“Medicis”) pursuant to which the Company agreed to acquire from Medicis all the outstanding shares of Medicis Technologies Corporation (f/k/a LipoSonix, Inc.) (“LipoSonix”), subject to the terms and conditions of the Purchase Agreement. In connection with the acquisition, a separate subsidiary of Medicis has agreed to transfer certain assets and assign certain agreements related to LipoSonix (collectively, the “Transaction”). The Company closed the Transaction on November 1, 2011. The transaction is to be accounted for as a business combination under accounting principles generally accepted in the United States. A more detailed description of and summary of the accounting for the acquisition is provided in the accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Statements.
